Skip to main content

Aliqopa (copanlisib) and Alcohol/Food Interactions

There are 2 alcohol/food/lifestyle interactions with Aliqopa (copanlisib) which include:


copanlisib food

Moderate Food Interaction

Grapefruit juice can increase the blood levels of copanlisib. This may increase side effects such as nausea, vomiting, diarrhea, mouth sores, high blood sugar, high blood pressure, lung or breathing problems, severe skin reactions, and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. You should avoid the consumption of grapefruit and grapefruit juice during treatment with copanlisib. Talk to your doctor or pharmacist if you have questions on this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data


High Blood Pressure (Hypertension)

Moderate Potential Hazard, Moderate plausibility

copanlisib - hypertension

Hypertension has occurred in patients treated with copanlisib. Before starting copanlisib patients should achieve optimal blood pressure control and dose should be reduced, or therapy temporarily discontinued depending on the severity and persistence of hypertension. It is recommended to monitor blood pressure before and after the infusion with copanlisib.

Aliqopa (copanlisib) drug interactions

There are 272 drug interactions with Aliqopa (copanlisib)

Aliqopa (copanlisib) disease interactions

There are 5 disease interactions with Aliqopa (copanlisib) which include:

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.